Boehringer Ingelheim

Oncology

At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.

News

New data with Zealand/Boehringer's survodutide reinforce its metabolic benefits, but a high discontinuation rate has raised concerns.

News

The CHMP recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral weight loss therapy.

Patients

The podcast welcomes Dr Ramy Younes, corporate VP, global head of clinical development, cardiorenalmetabolism, at Boehringer Ingelheim.

News

Boehringer and Brainomix are planning a prospective trial of an AI to diagnose pulmonary fibrosis, after positive results in an observational study.

News

Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.